Select Committee · Health and Social Care Committee
Future Cancer: NICE medicines appraisal (Enhertu)
Status: Closed
Opened: 30 Apr 2024
Closed: 30 May 2024
The committee will consider the impact of changes made by NICE to evaluate drugs used to treat patients with terminal illness like cancer in this session. The Future Cancer inquiry received evidence from drugs’ companies that changes by NICE in 2022 on the cost-effectiveness of drugs for severe diseases do not sufficiently weight treatments used … Show more
Oral evidence sessions
| Date | Witnesses | |
|---|---|---|
| 8 May 2024 | Baroness Delyth Morgan · Breast Cancer Now, David Brocklehurst · AstraZeneca UK, Dr Sam Roberts · National Institute for Health and Care Excellence (NICE), Haran Maheson · Daiichi Sankyo UK, Helen Knight · National Institute for Health and Care Excellence (NICE) | View ↗ |
Who gave evidence
| Witness | Organisation | Sessions |
|---|---|---|
| Baroness Delyth Morgan · Chief Executive | Breast Cancer Now | 1 |
| David Brocklehurst · Head of Oncology | AstraZeneca UK | 1 |
| Dr Sam Roberts · Chief Executive | National Institute for Health and Care Excellence (NICE) | 1 |
| Haran Maheson · Vice President, Oncology | Daiichi Sankyo UK | 1 |
| Helen Knight · Director of Medicines Evaluation | National Institute for Health and Care Excellence (NICE) | 1 |
Correspondence
| Date | Direction | Title |
|---|---|---|
| 22 May 2024 | — | NICE on Enhertu and the next steps 14.04.24 |
| 9 May 2024 | — | Daiichi Sankyo UK & AstraZeneca on HER2-low metastatic breast cancer NICE decis… |